Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.75 |
| ▸ | TCF7 | P36402 | 2/20 | 0.75 |
| ▸ | CLPP | Q16740 | 2/20 | 0.75 |
| ▸ | BCL9 | O00512 | 1/20 | 0.75 |
| ▸ | TCF4 | P15884 | 1/20 | 0.75 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12222035 | 0.93 | CYP3A4 (0.74) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL763057 | 0.93 | CTNNB1 (0.69) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL750985 | 0.92 | CTNNB1 (0.74) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL747784 | 0.92 | CTNNB1 (0.74) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL12037197 | 0.91 | CLPP (0.71) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL14620318 | 0.91 | CLPP (0.70) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL746577 | 0.88 | CLPP (0.67) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL23913420 | 0.88 | CTNNB1 (0.63) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL10224729 | 0.87 | CLPP (0.72) | CTNNB1TCF7CLPPBCL9TCF4 | |
| SCHEMBL749351 | 0.87 | CLPP (0.69) | CTNNB1TCF7CLPPBCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| WO-2009051397-A9 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009051397-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | CTNNB1 4355/4885TCF7 2392/4885CLPP 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.